In November 2011, Cellectis bioresearch acquired Cellartis. Cellectis bioresearch can now offer stem cell researchers a new and growing product portfolio:

Mesenchymal progenitors

A homogeneous and robust source for in vitro use in research applications...

Culture system

Feeder free and defined culture system for efficient expansion and scale up...

Monoclonal antibodies

For the identification, characterization and isolation of undifferentiated hES and hiPS cells...

Human ES and iPS cells

Access pluripotent stem cells for non-clinical basic research and directed differentiation...

We also offer hepatocytes- and cardiomyocytes-based cellular models for ADMETox studies and disease modelling.

Hepatocytes

Effective tools for the in vitro evaluation of hepatotoxicity ...

Cardiomyocytes

Physiologically relevant model to study cardiac toxicity...

Cellartis, a Swedish company founded in 2001, was formed as a spin-off from the University of Gothenburg. From its inception the company has worked on pluripotent stem cells and technologies for drug discovery research, toxicity testing and regenerative medicine. Cellartis has proven expertise in many different areas including:

• controlling stem cell differentiation into liver and heart cells which offer unrivalled performance in toxicity testing applications;
• ownership and exploitation of the world's largest stem cell bank (30 proprietary lines);
• effective industrial rollout of their technologies;
• regenerative medicine programs in collaboration with leading global partners, using the immense potential of stem cells for the restoration of damaged tissues and organs.